Proposed Agenda & Faculty, July 14-15 2023
08:00am
Registration
08:50am
Opening Introduction to the meeting – Ryan Fitzpatrick, CEO, MD Education
Session I
09:00am
Richters syndrome
Debbie Stephens – University of Utah
09:15am
SCT in CLL
Chitra Hosing – MD Anderson Cancer Center
09:30am
Frontline therapy
Jennifer Brown – Dana Farber Cancer Institute
09:45am
Treatment of patients with P53 aberrations
Bill Wierda – MD Anderson Cancer Center
10:00am
Panel Discussion
10:20am
Coffee Break
10:40am
Symposia
Session II
11:30am
CART in CLL
David Maloney – Fred Hutchinson Cancer Center
11:45am
Small molecule combinations
Nitin Jain – MD Anderson Cancer Center
12:00pm
Non-covalent BTK inhibitors
Jennifer Woyach – The Ohio State University
12:15pm
Covalent BTK inhibitors comparison
Kerry Rogers – The Ohio State University
12:30pm
Panel Discussion
12:50pm
Lunch Break
13:40pm
Symposia
Session III
14:30pm
MRD in CLL
Nathalie Johnson – McGill
14:45pm
CLL in 10 years
John Byrd – University of Cincinnati
15:00pm
Toxicities of Targeted Agents
Alessandra Ferrajoli – MD Anderson Cancer Center, Houston, Texas
15:15pm
Real World Data with small molecules
Danielle Brander – Duke University School of Medicine
15:30pm
Panel Discussion
15:50pm
Coffee Break
Session IV
16:10pm
Supportive care in CLL, vaccines etc
Clare Sun – National Heart, Lung and Blood Institute
16:25pm
Spicing alterations in CLL pathogenesis
Lili Wang – City of Hope
16:40pm
Monoclonal B cell lymphocytosis risk of disease progression, and other clinical consequences
Sameer Parikh – Mayo Clinic
16:55pm
Panel Discussion
17:15pm
Adjourn
17:20pm
Symposia
Session V
09:00am
Cell free DNA (at diagnosis for disease burden assessment, for molecular classification, for minimal residual disease monitoring)
Ash Alizadeh – Stanford Medicine
09:15am
Molecular classification of lymphomas (DLBCL, Hodgkin lymphoma)
David Scott – BC Cancer
09:30am
Molecular classification of lymphomas (FL, PTCL, MCL)
Sandeep Dave – Duke University School of Medicine
09:45am
Unresolved trial strategies for FL (Early POD, low risk disease)
Paolo Strati – MD Anderson Cancer Center
10:00am
Panel Discussion
10:20am
Coffee Break
10:40am
Symposia
Session VI
11:30am
CAR T cells in lymphoma – What to do now and what’s next Results of 1L trials, challenges in SOC 2L therapy, new trials in 3L+)
Sattva Neelapu – MD Anderson Cancer Center
11:45am
Clinical management of CAR T (approaches to toxicity management, outpatient CAR T)
Caron Jacobson – Dana Farber Cancer Institute
12:00pm
Emerging trials in lymphoma ECOG/industry (FL, MCL)
Peter Martin – Weill Cornell Medicine
12:15pm
Emerging trials in lymphoma Alliance/industry (DLBCL, other indolent)
John Leonard – Weill Cornell Medicine
12:30pm
Panel Discussion
12:45pm
Lunch Break
13:35pm
Symposia
Session VII
14:25pm
Emerging trials in lymphoma SWOG/industry (HL, PTCL)
Elizabeth Brem – UCI Health Cancer Center
14:40pm
Management strategies for MCL – where should we go next? (transplant and CAR T, intensive fixed duration therapy, continuous oral approaches)
Julie Vose – University of Nebraska
14:55pm
Current and future strategies in T-cell lymphomas (chemotherapy, should transplant be an option, novel agents)
Swami Iyer – MD Anderson Cancer Center
15:00pm
Panel Discussion
15:20pm
Coffee Break
Session VIII
15:40pm
Approaches in first line Hodgkin lymphoma (approaches to reduce therapy intensity/duration, late complications/survivorship)
Ranjana Advani – Stanford University
15:55pm
Integrating biomarkers into clinical trials (DLBCL, HL)
Ash Alizadeh – Stanford Medicine
16:10pm
Novel approaches for relapsed HL (new uses of approved agents,new agents)
Craig Moskowitz – University of Miami